Blockade of interleukin 1 receptor in Still's disease affects activation of peripheral T-lymphocytes.
Youssef
Jihad
J
Lazaro
Estibaliz
E
Blanco
Patrick
P
Viallard
Jean-François
JF
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy* / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology*
D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D016572:Cyclosporine; D011241:Prednisone